01核心产品爆发诺诚健华发布2025年中期业绩报告，实现营收7.3亿元，同比增长74.3%；归母净亏损3009.14万元，较2024年同期的2.62亿元亏损大幅缩窄。值得一提的是，其研发费用4.5亿元，同比增长6.9%，占营业收入比例62%。奥布替尼是诺诚健华首个核心上市产品，也是其业绩提升的关键因素。奥布替尼上半年实现销售收入6.37亿元，同比增长52.84%，占总营收的87%。奥布替尼为一种高...
Source Link01核心产品爆发诺诚健华发布2025年中期业绩报告，实现营收7.3亿元，同比增长74.3%；归母净亏损3009.14万元，较2024年同期的2.62亿元亏损大幅缩窄。值得一提的是，其研发费用4.5亿元，同比增长6.9%，占营业收入比例62%。奥布替尼是诺诚健华首个核心上市产品，也是其业绩提升的关键因素。奥布替尼上半年实现销售收入6.37亿元，同比增长52.84%，占总营收的87%。奥布替尼为一种高...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.